Longitudinal impact of sodium bicarbonate therapy on health-related quality of life in pre-dialysis chronic kidney disease with metabolic acidosis: a pragmatic trial in Malaysia.
Jaime Yoke May Chan, Yi Jing Tan, Farida Islahudin et al.
✦ AI-curated · Sources linked
In 30 seconds
This pragmatic clinical trial evaluated the impact of sodium bicarbonate therapy on health-related quality of life (HRQoL) in 74 pre-dialysis chronic kidney disease (CKD) patients with metabolic acidosis over 18 months. Despite increased serum bicarbonate levels, sodium bicarbonate did not significantly improve HRQoL scores compared to standard care. Worsening CKD stage was associated with lower HRQoL.
Key findings
- Sodium bicarbonate therapy did not significantly improve KDQOL-36 or EQ-VAS scores compared to control.
- Only one-third of treated patients achieved the target serum bicarbonate range of 22-26 mmol/L.
- Worsening CKD stage was significantly associated with lower HRQoL, particularly in the KDQOL-36 Effects and Burden subscales.
- Gastrointestinal symptoms and peripheral oedema were common among treated patients but did not significantly impact HRQoL.
Why it matters
Understanding the relationship between treatment and quality of life in CKD patients is crucial, as improvements in laboratory values do not always correlate with enhanced patient well-being. This highlights the importance of considering disease progression in patient care.